Regeneron Pharmaceuticals, Inc. (REGN) – Continued to grow through its largest brands

REGN completed their initial contract to supply REGEN-COV to the US government in Q1FY21. The Phase 3 results have now shown that the antibody cocktail dramatically reduces hospitalizations or death in nonhospitalized COVID-infected patients and reduces symptomatic infections when given as a preventative measure

Highlights

Valuation

– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– Discounted Cash Flow Analysis
– P/E Analysis
– Peer Valuation.
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Key Metrics
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance 

No of Pages : 36